title: Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats.
abstract: Although increasing evidence indicates that psychiatric symptoms are crucial characteristic of the early stage of Parkinson's disease (PD) and precede motor impairments, the neuronal firing activity of the basolateral nucleus of the amygdala (BLA) in the psychiatric symptom of PD and the involved mechanism are still unclear. In the present study, we examined the changes in emotional and cognitive tests not focused on motor fluency and firing activity of projection neurons in the BLA rats with 6-hydroxydopamine (6-OHDA) injected bilaterally into dorsal striatum, and the effects of apomorphine and the medial prefrontal cortex (mPFC) on these changes. Injection of 6-OHDA (10.5 μg) into the dorsal striatum produced 18-22% and 26-30% loss of tyrosine hydroxylase immunoreactive neurons in the ventral tegmental area and substantia nigra pars compacta of rats, respectively. The striatal lesions induced anxiety-like responses in the rats but did not result in depressive-like behavior or cognitive impairments. In the lesioned rats, the firing rate of BLA projection neurons decreased significantly compared with sham-operated rats, and the firing pattern of BLA projection neurons was not changed. No significant differences were observed either in behaviors or firing activity of BLA projection neurons by further ibotenic acid lesions of the mPFC in the lesioned rats. Systemic administration of cumulative apomorphine (10-160 μg/kg) inhibited the firing rate of BLA projection neurons in sham-operated, 6-OHDA-lesioned and combined 6-OHDA- and mPFC-lesioned rats, but the latter needed more apomorphine stimulation. These data suggest that the anxiety in early stage of PD is possibly related to the decrease in firing activity of BLA projection neurons, which may be regulated by the activation of dopamine receptor in the mPFC.
authors.affiliation: Department of Physiology and Pathophysiology, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China.
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Liu
authors.forename: Qiao Jun
authors.initials: QJ
authors.lastname: Zhang
authors.forename: Jian Jun
authors.initials: JJ
authors.lastname: Feng
authors.forename: Zhen Hua
authors.initials: ZH
authors.lastname: Gui
authors.forename: Umar
authors.initials: U
authors.lastname: Ali
authors.forename: Yong
authors.initials: Y
authors.lastname: Wang
authors.forename: Ling Ling
authors.initials: LL
authors.lastname: Fan
authors.forename: Chen
authors.initials: C
authors.lastname: Hou
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
mesh_terms: D000200:Action Potentials / Q000502:physiology*; D018663:Adrenergic Agents / Q000494:pharmacology; D000679:Amygdala / Q000033:anatomy & histology / Q000473:pathology / Q000502:physiology*; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D003071:Cognition / Q000502:physiology*; D003342:Corpus Striatum / Q000033:anatomy & histology* / Q000502:physiology; D004644:Emotions / Q000502:physiology*; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D006801:Humans; D007051:Ibotenic Acid / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009434:Neural Pathways / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009483:Neuropsychological Tests; D016627:Oxidopamine / Q000494:pharmacology; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013378:Substantia Nigra / Q000033:anatomy & histology* / Q000502:physiology
chemical_list: D018663:Adrenergic Agents; D000978:Antiparkinson Agents; D018690:Excitatory Amino Acid Agonists; D007051:Ibotenic Acid; D016627:Oxidopamine; D001058:Apomorphine